文献速递心外重症与机械循环支持

在晚期心脏治疗改善结局网络(ACTION)中扩大HeartMate 3心室辅助装置在儿童及成人患者中的使用

Expanding use of the HeartMate 3 ventricular assist device in pediatric and adult patients within the Advanced Cardiac Therapies Improving Outcomes Network (ACTION).
PubMed 文献 · J Heart Lung Transplant · 2023-07-05

该研究基于ACTION多中心学习网络数据库,纳入2017年12月至2022年5月植入HeartMate 3(HM3)心室辅助装置的170例患者,中位年龄15.3岁,中位体表面积1.68 m²。中位支持时间102.5天,61.2%接受心脏移植,7.6%死亡;体表面积<1.4 m²的患者感染、肾功能不全及缺血性卒中发生率更高。

要点

  • 170例HM3植入患者中位年龄15.3岁,61.2%接受心脏移植,7.6%在装置支持期间死亡。
  • 最常见不良事件为大出血(20.8%)和驱动线感染(12.9%),缺血性卒中占6.5%。
  • 体表面积<1.4 m²的患者感染、肾功能不全和缺血性卒中发生率更高。

核心结论

  • 在以儿童为主的HM3心室辅助装置支持队列中,结局良好,装置支持期间死亡率<8%。
  • 卒中、感染和肾功能不全等装置相关不良事件在体型较小的患者中更常见,提示有改进照护的机会。

研究设计与样本

  • 多中心学习网络数据库查询研究,检索Advanced Cardiac Therapies Improving Outcomes Network数据库2017年12月至2022年5月间的HM3植入病例。
  • 共纳入170例患者,按植入时体表面积分为<1.4 m²、1.4-1.8 m²和>1.8 m²三组,收集体床特征、植入后病程和不良事件。

主要发现

  • 170例患者中位年龄15.3岁,27.1%为女性,中位体表面积1.68 m²,最小患者体表面积0.73 m²(17.7 kg),71.8%诊断为扩张型心肌病。
  • 中位支持时间102.5天,61.2%接受心脏移植,22.9%仍在装置支持中,7.6%死亡,2.4%因心脏功能恢复而移除装置,其余转至其他机构或转换为其他装置类型。
  • 最常见不良事件为大出血(20.8%)和驱动线感染(12.9%),缺血性卒中和出血性卒中分别占6.5%和1.2%。
  • 体表面积<1.4 m²的患者感染、肾功能不全和缺血性卒中发生率更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We report current outcomes in patients supported with the HeartMate 3 (HM3) ventricular assist device in a multicenter learning network. METHODS: The Advanced Cardiac Therapies Improving Outcomes Network database was queried for HM3 implants between 12/2017 and 5/2022. Clinical characteristics, postimplant course, and adverse events were collected. Patients were stratified according to body surface area (BSA) (<1.4 m2, 1.4-1.8 m2, and >1.8 m2) at device implantation. RESULTS: During the study period, 170 patients were implanted with the HM3 at participating network centers, with median age 15.3years; 27.1% were female. Median BSA was 1.68 m2; the smallest patient was 0.73 m2 (17.7 kg). Most (71.8%) had a diagnosis of dilated cardiomyopathy. With a median support time of 102.5days, 61.2% underwent transplantation, 22.9% remained supported on device, 7.6% died, and 2.4% underwent device explantation for recovery; the remainder had transferred to another institution or transitioned to a different device type. The most common adverse events included major bleeding (20.8%) and driveline infection (12.9%); ischemic and hemorrhagic stroke were encountered in 6.5% and 1.2% of patients, respectively. Patients with BSA <1.4 m2 had a higher incidence of infection, renal dysfunction, and ischemic stroke. CONCLUSIONS: In this updated cohort of predominantly pediatric patients supported with the HM3 ventricular assist device, outcomes are excellent with <8% mortality on device. Device-related adverse events including stroke, infection, and renal dysfunction were more commonly seen in smaller patients, highlighting opportunities for improvements in care.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. O'Connor MJ, Shezad M, Ahmed H, et al. Expanding use of the HeartMate 3 ventricular assist device in pediatric and adult patients within the Advanced Cardiac Therapies Improving Outcomes Network (ACTION). J Heart Lung Transplant. 2023. PMID: 37419295. doi:10.1016/j.healun.2023.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。